AC Immune (ACIU) Research & Development (2015 - 2026)
AC Immune (ACIU) posted quarterly Research & Development of -$15.0 million for Q1 2026, up 15.28% year-over-year from -$13.0 million in Q1 2025, and down 12.84% quarter-over-quarter from -$13.3 million in Q4 2025.
AC Immune (ACIU) Research & Development (2015 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Research & Development for 12 consecutive years, with -$15.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 15.28% year-over-year to -$15.0 million; the TTM figure through Mar 2026 stood at -$65.0 million (up 9.01% YoY), while the FY2025 annual figure was -$68.1 million, up 4.7% from the prior year.
- Research & Development slipped to -$15.0 million in Q1 2026 per ACIU's latest filing, from -$13.3 million in the prior quarter.
- Across five years, Research & Development topped out at -$13.3 million in Q4 2025 and bottomed at -$20.3 million in Q2 2025.
- Historically, Research & Development has averaged -$16.3 million across 5 years, with a median of -$16.3 million in 2025.
- Annual changes were most pronounced in 2022 — Research & Development climbed 28.01% — and 2024, when it decreased 24.54%.
- AC Immune's Research & Development stood at -$15.7 million in 2022, then retreated by 5.08% to -$16.5 million in 2023, then fell by 9.15% to -$18.0 million in 2024, then gained by 26.24% to -$13.3 million in 2025, then declined by 12.84% to -$15.0 million in 2026.
- Business Quant data shows ACIU's Research & Development at -$15.0 million in Q1 2026, -$13.3 million in Q4 2025, and -$16.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | AC Immune | 253.89 Mn | 253.89 Mn | - | 42.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.97 Mn |
| Mar 31, 2026 | -15.00 Mn |
| Dec 31, 2025 | -13.29 Mn |
| Sep 30, 2025 | -16.34 Mn |
| Jun 30, 2025 | -20.32 Mn |
| Mar 31, 2025 | -17.70 Mn |
| Dec 31, 2024 | -18.02 Mn |
| Sep 30, 2024 | -16.72 Mn |
| Jun 30, 2024 | -18.95 Mn |
| Mar 31, 2024 | -17.37 Mn |
| Dec 31, 2023 | -16.51 Mn |
| Sep 30, 2023 | -14.05 Mn |
| Jun 30, 2023 | -15.22 Mn |
| Mar 31, 2023 | -15.00 Mn |
| Dec 31, 2022 | -15.71 Mn |
| Sep 30, 2022 | -14.90 Mn |
| Jun 30, 2022 | -16.29 Mn |
| Mar 31, 2022 | -16.38 Mn |
| Dec 31, 2021 | -21.82 Mn |
| Sep 30, 2021 | -16.47 Mn |